Skip to main content
HR 4629 116th Congress House Health Health care costs and insurance Health care coverage and access Health care quality Health programs administration and funding Medicare Performance measurement Prescription drugs

Star Rating for Biosimilars Act

Introduced: October 8, 2019 Introduced by: Tonko, Paul Democratic · New York See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 18, 2019
Sponsor introductory remarks on measure. (CR H8232)
Oct 9, 2019
Referred to the Subcommittee on Health.
Oct 8, 2019
Referred to the Subcommittee on Health.
Oct 8, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 8, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Star Rating for Biosimilars Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.

The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.

What's happening now October 18, 2019

Sponsor introductory remarks on measure. (CR H8232)

 Related & companion bills 3
  • HR 3 Related bill Elijah E. Cummings Lower Drug Costs Now Act
  • S 2543 Related bill Prescription Drug Pricing Reduction Act of 2019
  • S 4199 Related bill Prescription Drug Pricing Reduction Act of 2020
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 4629: Star Rating for Biosimilars Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-4629/
MLA
"H.R. 4629: Star Rating for Biosimilars Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-4629/.
Bluebook (legal)
H.R. 4629, 116th Cong. (2026), https://openamerica.io/bill/116-HR-4629/.
Markdown link
[H.R. 4629: Star Rating for Biosimilars Act](https://openamerica.io/bill/116-HR-4629/)
Report a problem